بررسی اثر درمانی سایتوکین IL22 بر زخم ناشی از لیشمانیا ماژور در موش BALB/c

Abstract Background and purpose: IL22 is the family member of IL10 created by Th17, Th22, NK cells and its role has been recently demonstrated in protection and innate defense mechanisms, control of bacterial and viral infection, homeostasis and tissue repair. This research investigated the impacts of Il22 treatment on lesion originated from L-major in BALB/c mice. Materials and methods: Twenty four Iranian female BALB/c mice, 8 weeks old were challenged by 2x10 6 Promastigotes of L-Major MRHO/IR/75/ER by the dose of 100 microliters in stationary phase. They were infected percutaneously and then were divided into three groups each with eight recombinant mice IL-22 that received two different doses of 5ng/mg and 10ng/mg IM. Immune evaluation of cellular and humoral immunity was done by assessing IL-4 Cytokine, IFN-ɤ and culturing of spleen lymphocyte cells. Also, investigation of IgG2a, IgG total was carried out by Elisa method and MTT colorimetric assay. Furthermore, clinical investigations including measuring wound healing, life span of mice and recording of mortality rate was done. Results: The results indicates that the growth of wound reduced in the group treated with IL22 and the most impact was seen in the group under treatment with IL22 (5ng). IL22 (5ng) increased the production of IFN-ɤ but deceased the production of IL4. Findings from LSD test showed that the rate of IFN-ɤ and IGg total in the group treated with IL22-5ng was significantly different from other groups. There was no significant difference between Il22-5ng and IL22-10ng regarding the rate of IL4 and the rate of IgGg2a. Furthermore, MTT in the group treated with IL22-5ng was significantly different from other groups. Conclusion: IL22-5ng leads to Cytokine Th1 response through increasing the production of IFN-ɤ and decreasing the production of IL4, which result in protective response against L-major. Hence, it may have effective impacts in treatment if used with a combined anti leishmania drug.